This week’s China biopharma roundup from PharmaBoardroom content partner Selesta covers Novartis’ USD 5.4bn expansion with Argo in cardiovascular siRNA, Hengrui’s USD 1.1bn out-licensing of its cardiac myosin inhibitor, Novatim’s…
New Idorsia CEO Srishti Gupta is emphasising “financial discipline” as she looks to turn around the fortunes of one of Europe’s top biotechs. Challenging Times Gupta, who spent almost…
Europe risks “slow death” in innovation unless it builds its own Silicon Valley, argues digital health investor Laurent van Lerberghe. With Macron pushing Anglo-French tech sovereignty, the UK and France…
This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers Gilead’s USD 350mn bet on in vivo CAR-T, GenFleet and Bao Pharma advancing Hong Kong IPOs, Fosun’s…
Chinese biopharma innovators are making real progress toward global expansion. However, as Vera Zhang of Bristol-Myers Squibb (China) Investment Co., Ltd. writes in DIA’s Global Forum magazine, moving beyond exporting…
The EU’s Health Technology Assessment Regulation (HTAR), which kicked off in January 2025, has launched joint clinical assessments (JCAs) for oncology and advanced therapies; yet six months in, implementation remains…
As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the…
Jiangsu Hengrui Pharmaceuticals is no longer just a local biopharma heavyweight. With a record-breaking and 450x oversubscribed IPO raising USD 1.27 billion, a flurry of global licensing deals with the…
The CGT field is undergoing a critical transformation from boom to thoughtful reset. While early enthusiasm brought a rush of investment and regulatory attention, the sector is now refining its…
A roundup of some ot the biggest stories coming out of China’s biopharma industry: Chinese pharma shifts to local reagent suppliers; WuXi Biologics launches new stable cell line platform; Fosun…
The latest stories from healthcare and the life sciences in the US. Vinay Prasad is reinstated as head of the FDA’s CBER following a brief resignation; HHS fires Gray Delany…
France is betting big on industrial transformation. With its sweeping EUR 54 billion France 2030 investment plan, the government has laid down a clear ambition: to become a global leader…
See our Cookie Privacy Policy Here
